Baseline patient and disease characteristics in all patients (clinical cutoff date 15 March 2021; safety evaluable population)
| N (%) of patients unless stated . | N = 88 . |
|---|---|
| Median age, y (range) | 66.5 (24-96) |
| Male | 60 (68.2) |
| ECOG PS | |
| 0 | 31 (35.2) |
| 1 | 57 (64.8) |
| Ann Arbor stage | |
| I | 4 (4.5) |
| II | 10 (11.4) |
| III | 19 (21.6) |
| IV | 55 (62.5) |
| NHL subtype | |
| DLBCL | 65 (73.9) |
| trFL | 23 (26.1) |
| Cell-of-origin | |
| GCB | 49 (55.7) |
| Non-GCB | 29 (33.0) |
| Unknown | 10 (11.4) |
| MYC and BCL2 and/or BCL6 translocation | 17 (19.3) |
| Bulky disease (>10 cm) | 8 (9.1) |
| Median number of prior lines of therapy, n (range) | 3 (2-13) |
| 2 previous lines, n (%) | 31 (35.2) |
| 3 previous lines, n (%) | 28 (31.8) |
| >3 previous lines, n (%) | 29 (33.0) |
| Prior cancer therapy | |
| Anti-CD20 antibody | 88 (100.0) |
| Anthracycline | 88 (100.0) |
| CAR-T cell therapy | 26 (29.5) |
| Prior ASCT | 15 (17.0) |
| R/R∗ status | |
| Refractory to last prior therapy | 70 (79.5) |
| Refractory to any previous anti-CD20 | 77 (87.5) |
| Refractory to previous CAR-T cell therapy | 18/26 (69.2) |
| N (%) of patients unless stated . | N = 88 . |
|---|---|
| Median age, y (range) | 66.5 (24-96) |
| Male | 60 (68.2) |
| ECOG PS | |
| 0 | 31 (35.2) |
| 1 | 57 (64.8) |
| Ann Arbor stage | |
| I | 4 (4.5) |
| II | 10 (11.4) |
| III | 19 (21.6) |
| IV | 55 (62.5) |
| NHL subtype | |
| DLBCL | 65 (73.9) |
| trFL | 23 (26.1) |
| Cell-of-origin | |
| GCB | 49 (55.7) |
| Non-GCB | 29 (33.0) |
| Unknown | 10 (11.4) |
| MYC and BCL2 and/or BCL6 translocation | 17 (19.3) |
| Bulky disease (>10 cm) | 8 (9.1) |
| Median number of prior lines of therapy, n (range) | 3 (2-13) |
| 2 previous lines, n (%) | 31 (35.2) |
| 3 previous lines, n (%) | 28 (31.8) |
| >3 previous lines, n (%) | 29 (33.0) |
| Prior cancer therapy | |
| Anti-CD20 antibody | 88 (100.0) |
| Anthracycline | 88 (100.0) |
| CAR-T cell therapy | 26 (29.5) |
| Prior ASCT | 15 (17.0) |
| R/R∗ status | |
| Refractory to last prior therapy | 70 (79.5) |
| Refractory to any previous anti-CD20 | 77 (87.5) |
| Refractory to previous CAR-T cell therapy | 18/26 (69.2) |
ECOG PS, Eastern Cooperative Oncology Group performance status; NHL, non-Hodgkin lymphoma.
Defined as not achieving a response (complete or partial) or progressing within ≤6 months of applicable treatment.